HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1,957: | Line 1,957: | ||
|- | |- | ||
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING | |[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||PENDING | ||
| || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | | || || || | ||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma | |||
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | |(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma | ||
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | |(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez | ||
| Line 2,054: | Line 2,054: | ||
|- | |- | ||
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING | |[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||PENDING | ||
| || || || | | || || || | ||
|SG | |SG | ||
| || | | ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga) | ||
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | |NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang | ||
|NEW (No Prior) | |NEW (No Prior) | ||
| Line 2,064: | Line 2,064: | ||
|- | |- | ||
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING | |[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||PENDING | ||
| || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | | || || || ||SG | ||
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page | |||
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | |(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants | ||
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | |(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG | ||
| Line 2,073: | Line 2,073: | ||
|- | |- | ||
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING | |[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING | ||
| || || || | | || || || | ||
|SG | |SG | ||
| || | | ||Note: author needs to include POEMS, TEMPI, and look for AESOP content | ||
|(1) POEMS Syndrome + (2) TEMPI Syndrome | |(1) POEMS Syndrome + (2) TEMPI Syndrome | ||
|(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | |(1 and 2) Sohini Anand, MBBS Tharanga Niroshini Senaratne, PhD | ||